HCV Treatment
AASLD 2016: Curing Hepatitis C May Help Reduce Kidney Disease Progression
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
People who achieved sustained virological response to interferon-based hepatitis C treatment experienced significantly less decline in kidney function, especially if they had liver cirrhosis, according to study findings presented at the 2016 AASLD Liver Meeting last month in Boston.
AASLD 2016: 6 Weeks of Sofosbuvir/Ledipasvir Cures Genotype 1 Acute Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 November 2016 00:00
- Written by Liz Highleyman
A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to study results presented at the 2016 AASLD Liver Meeting this month in Boston.
AASLD 2016: Primary Care Providers Can Effectively Treat Patients with Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 22 November 2016 00:00
- Written by Liz Highleyman
Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral (DAA) therapy for hepatitis C with a high level of treatment success and provider satisfaction, according to a presentation at the 2016 AASLD Liver Meeting this month in Boston.
AASLD 2016: Non-Adherence Is Most Important Risk Factor for Sofosbuvir/Ledipasvir Failure
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 November 2016 00:00
- Written by Keith Alcorn
Research carried out by researchers at Mount Sinai Medical Center in New York found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C. The main reasons cited for non-adherence were failing to take medication as prescribed and hospitalization, according to a report at the 2016 AASLD Liver Meeting in Boston earlier this month.
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Sunday, 20 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/20/16
More Articles...
- AASLD 2016: U.S. Veterans Health System and Australia Show Potential for Rapid Hepatitis C Elimination
- AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients
- AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C
- AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes
Web Design and Development by